Omeros (OMER) Total Current Liabilities (2010 - 2026)
Omeros recorded quarterly Total Current Liabilities of $59.4 million in Q1 2026, down 23.85% quarter-over-quarter from $78.1 million in Q4 2025, and down 28.57% year-over-year from $83.2 million in Q1 2025.
Omeros' Total Current Liabilities history runs 17 years deep, the most recent figure standing at $59.4 million for Q1 2026.
- In Q1 2026, Total Current Liabilities fell 28.57% year-over-year to $59.4 million; the TTM figure through Mar 2026 stood at $59.4 million (down 28.57% YoY), while the FY2025 annual figure was $78.1 million, down 1.84% from the prior year.
- Total Current Liabilities came in at $59.4 million for Q1 2026 at Omeros, down from $78.1 million in the prior quarter.
- In the past five years, Total Current Liabilities ranged from a high of $147.2 million in Q3 2023 to a low of $35.1 million in Q1 2022.
- A 5-year average of $80.8 million and a median of $78.1 million in 2025 frame the typical range for Total Current Liabilities.
- Across the five-year window, Total Current Liabilities surged 296.94% in 2023 and sank 62.21% in 2024, its largest moves.
- Omeros' Total Current Liabilities stood at $136.4 million in 2022, then slumped by 60.91% to $53.3 million in 2023, then jumped by 49.16% to $79.5 million in 2024, then decreased by 1.84% to $78.1 million in 2025, then fell by 23.85% to $59.4 million in 2026.
- According to Business Quant data, Total Current Liabilities over the past three periods registered $59.4 million, $78.1 million, and $80.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 16.35 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 1.70 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 636.40 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 66.94 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 13.42 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 3.88 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 5.11 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 1.35 Bn |
| 10 | Omeros | 772.03 Mn | 636.71 Mn | 9.31 Mn | 59.44 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 59.44 Mn |
| Dec 31, 2025 | 78.06 Mn |
| Sep 30, 2025 | 80.76 Mn |
| Jun 30, 2025 | 85.50 Mn |
| Mar 31, 2025 | 83.22 Mn |
| Dec 31, 2024 | 79.53 Mn |
| Sep 30, 2024 | 55.62 Mn |
| Jun 30, 2024 | 59.48 Mn |
| Mar 31, 2024 | 59.06 Mn |
| Dec 31, 2023 | 53.32 Mn |
| Sep 30, 2023 | 147.18 Mn |
| Jun 30, 2023 | 143.54 Mn |
| Mar 31, 2023 | 139.19 Mn |
| Dec 31, 2022 | 136.38 Mn |
| Sep 30, 2022 | 39.51 Mn |
| Jun 30, 2022 | 38.50 Mn |
| Mar 31, 2022 | 35.07 Mn |
| Dec 31, 2021 | 51.79 Mn |
| Sep 30, 2021 | 42.82 Mn |
| Jun 30, 2021 | 47.70 Mn |
| Mar 31, 2021 | 43.43 Mn |
| Dec 31, 2020 | 36.74 Mn |
| Sep 30, 2020 | 47.72 Mn |
| Jun 30, 2020 | 38.05 Mn |
| Mar 31, 2020 | 57.94 Mn |
| Dec 31, 2019 | 55.46 Mn |
| Sep 30, 2019 | 46.75 Mn |
| Jun 30, 2019 | 40.67 Mn |
| Mar 31, 2019 | 44.51 Mn |
| Dec 31, 2018 | 37.36 Mn |
| Sep 30, 2018 | 24.59 Mn |
| Jun 30, 2018 | 24.44 Mn |
| Mar 31, 2018 | 24.63 Mn |
| Dec 31, 2017 | 26.31 Mn |
| Sep 30, 2017 | 24.69 Mn |
| Jun 30, 2017 | 24.75 Mn |
| Mar 31, 2017 | 16.97 Mn |
| Dec 31, 2016 | 16.07 Mn |
| Sep 30, 2016 | 16.06 Mn |
| Jun 30, 2016 | 16.07 Mn |
| Mar 31, 2016 | 17.52 Mn |
| Dec 31, 2015 | 16.25 Mn |
| Sep 30, 2015 | 22.27 Mn |
| Jun 30, 2015 | 20.10 Mn |
| Mar 31, 2015 | 20.07 Mn |
| Dec 31, 2014 | 18.32 Mn |
| Sep 30, 2014 | 14.40 Mn |
| Jun 30, 2014 | 12.17 Mn |
| Mar 31, 2014 | 10.23 Mn |
| Dec 31, 2013 | 11.87 Mn |
| Sep 30, 2013 | 11.90 Mn |
| Jun 30, 2013 | 10.90 Mn |
| Mar 31, 2013 | 10.59 Mn |
| Dec 31, 2012 | 8.36 Mn |
| Sep 30, 2012 | 21.81 Mn |
| Jun 30, 2012 | 17.25 Mn |
| Mar 31, 2012 | 18.74 Mn |
| Dec 31, 2011 | 18.99 Mn |
| Sep 30, 2011 | 15.82 Mn |
| Jun 30, 2011 | 14.34 Mn |
| Dec 31, 2010 | 15.37 Mn |